ClinicalTrials.gg
CompletedNCT03665480Updated Nov 12, 2026

The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML

A Phase 2/3 interventional study of G-SCF in Granulocyte Colony-stimulating Factor, Minimal Residual Disease and Acute Myeloid Leukemia, sponsored by Nanfang Hospital, Southern Medical University. Completed at 1 site in China. Open to participants aged 14 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Nanfang Hospital, Southern Medical University · Phase 2/3, Interventional, and Supportive care

How we know

Updated Nov 12, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
762
Allocation
Randomized
Ages
14 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 78 studies in Neoplasm, Residual with a site in China — 52 open to participants now, 56 under way, 3 of them phase 3. Neoplasm, Residual · China.

Enrollment
2nd of 48
762 · median 70
Started
2018
with 4 others
Phase 2/3
7 of 78
2 open now
Registered
8th of 78
by date
Lead sponsor
6 of 78
Nanfang Hospital, Southern Medical University

Among the 78 studies in Neoplasm, Residual with a site in China, this one is the 2nd largest by enrollment of the 48 interventional ones that give a count, is one of 5 that started in 2018, is one of 7 in phase 2/3, and was the 8th registered.

Neoplasm, Residual

294 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.

Browse Neoplasm, Residual studies →

Open to participants now

52 of the 78 studies in Neoplasm, Residual with a site in China are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 93 Neoplasm, Residual studies recruiting now, 59 (63%) set no upper age limit and 24 (26%) stop at 75 or younger; 18 take children under 18; 7 take healthy volunteers.

This study: 14 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Neoplasm, Residual with a site in China, or all of them as a file.
02

Study summary

Granulocyte-colony stimulating factor (G-CSF) is konwn to have no significant effect on leukemia stem cells and has been widely used in the patients with agranulocytosis after chemotherapy. Minimal residual disease (MRD), an index for early treatment response, plays an important role in prognostic prediction. Numbers of data have shown MRD at day 14 after induction therapy significantly predicts prognosis. However, the retrospetive data from the investigators showed that patients with G-CSF treatment after induction had higher MRD at day 14 but not significantly different at day 28, suggesting that G-CSF might work on the differenciation of hemapoetic stem cells and increase MRD levels at day 14. In this multicenter prospective randomized controlled study, the effect of G-CSF on MRD after induction therapy in newly diagnosed acute myeloid leukemia (AML) is evaluated.

Read the detailed description

Granulocyte-colony stimulating factor (G-CSF) is konwn to have no significant effect on leukemia stem cells and has been widely used in the patients with agranulocytosis after chemotherapy. Minimal residual disease (MRD), an good index for early treatment response, plays an important role in prognostic prediction. Numbers of data have shown MRD at day 14 after induction therapy significantly predicts prognosis. However, the retrospetive data from the investigators showed that patients with G-CSF treatment after induction had higher MRD at day 14 but not significantly different at day 28,suggesting that G-CSF might work on the differenciation of hemapoetic stem cells and increase MRD level at day 14. In this multicenter prospective study, the investigators randomizedly divide all participants with newly diagnosed acute myeloid leukemia (AML) into G-CSF treatment group and G-SCF-free group. In G-CSF treatment group, all participants are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28 with flow cytometry and quantity PCR if a fusion gene is available in both G-CSF treatment and G-CSF-free groups. Comparision of the difference of MRD levels between the two groups is performed to evaluate the effect of G-CSF on MRD.

03

Conditions studied

  • Granulocyte Colony-stimulating Factor
  • Minimal Residual Disease
  • Acute Myeloid Leukemia
04

Who can participate

Ages eligible
14 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Newly diagnosed AML exclusively of APL; 14-65 years old; Neutrophil \< 1.5 G/L at the day three after induction.

Exclusion criteria

Exclusion Criteria:

Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure); Patients with any conditions not suitable for the trial; NR at day 28 after induction.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
762 participants (actual)

Study arms

  • Experimental
    G-CSF treatment

    In G-CSF treatment group, all participants are treated with G-CSF at the dose of 5ug/kg per day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28 with flow cytometry and quantity PCR if a fusion gene is available.

    Drug: G-SCF

  • No intervention
    G-CSF-free

    In G-CSF-free group, no participants with newly diagnosed AML are treated with G-CSF after induction therapy.

Interventions

  • DrugG-SCF

    In G-CSF treatment group, all patients are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28, respectively, with flow cytometry and quantity PCR if a fusion gene is available.

06

What researchers measure

Primary outcomes

  1. MRD1

    MRD level is detested by flow cytometry at the day 14 after induction therapy.

    Time frame: Day 14 after induction

Secondary outcomes

  1. OS rate

    OS is the abbreviation of overall survival. OS rate is caculated as the ratio of survival participants versus total participants during the 2-year follow-up after diagosis.

    Time frame: 2 years

  2. DFS rate

    DFS is the abbreviation of disease-free survival. DFS rate is caculated as the ratio of participants with continuous complete remission (CR) versus total participants abtaining CR after induction during the 2-year follow-up after diagosis.

    Time frame: 2 years

  3. Time for neutropenia

    The lasting time for the patients with neutropenia after induction therapy

    Time frame: 30 days after induction

  4. Infection incidence

    The incidence of infection after induction

    Time frame: 30 days after induction

  5. MRD2

    MRD level is detested by flow cytometry at the day 28 after induction therapy.

    Time frame: Day 28 after induction

07

Study locations

1 site
  • Department of Hematology,Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2018 to primary completion in May 2022, 44 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Aug 2020 → May 2022 and completion Aug 2021 → Apr 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2018
First posted
Sep 11, 2018
StartActual
Sep 4, 2018
Primary completionActual
May 26, 2022was Aug 2020
CompletionActual
Apr 30, 2025was Aug 2021
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 12, 2026
Primary completion
Aug 2020→May 26, 2022 (actual)
Nov 12, 2026
Study completion
Aug 2021→Apr 30, 2025 (actual)
Nov 12, 2026
Enrollment
122 (estimated)→762 (actual)
Nov 12, 2026
Sponsor
Collaborators added: Guangdong Second Provincial General Hospital·First Affiliated Hospital of Guangxi Medical University·Shenzhen Second People's Hospital·First People's Hospital of Chenzhou; collaborators removed: Second Affiliated Hospital, Sun Yat-Sen University·Peking University Shenzhen Hospital
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Status unknown→Completed
    Primary completion Aug 2020→May 26, 2022 (now actual)
    Study completion Aug 2021→Apr 30, 2025 (now actual)
    Enrollment 122 (estimated)→762 (actual)
    Sponsor Collaborators added: Guangdong Second Provincial General Hospital·First Affiliated Hospital of Guangxi Medical University·Shenzhen Second People's Hospital·First People's Hospital of Chenzhou; collaborators removed: Second Affiliated Hospital, Sun Yat-Sen University·Peking University Shenzhen Hospital
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03665480
Collaborators
Guangzhou First People's Hospital, Shenzhen Hospital of Southern Medical University, Guangdong Second Provincial General Hospital, First Affiliated Hospital of Guangxi Medical University, Shenzhen Second People's Hospital, First People's Hospital of Chenzhou
Responsible party
Liu Qifa (professor, Nanfang Hospital, Southern Medical University) — Principal investigator
First posted
Sep 11, 2018
Start date
Sep 4, 2018
Primary completion
May 26, 2022
Completion
Apr 30, 2025
Last update
Nov 12, 2026

Study contacts

Qifa Liu
principal investigator · Nanfang Hospital, Southern Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion